By VETTAPHARMA reporter – Derek Roche: European Medicines Agency recommended approval of the first oral glucagon-like peptide-1 (GLP-1) receptor agonist treatment for weight management in the European Union through an extension of the marketing authorisation for Wegovy (semaglutide) tablets.
The oral formulation is intended for use alongside diet and physical activity in adults with obesity or those who are overweight with at least one weight-related comorbidity, expanding treatment access beyond injectable GLP-1 therapies.
Wegovy tablets become the first oral GLP-1 receptor agonist recommended for weight management, representing a significant shift toward non-injectable obesity therapies.
The recommendation was based on data from the OASIS clinical development programme, which evaluated oral semaglutide in adults with obesity and overweight. The studies assessed the therapy’s impact on body weight reduction and long-term weight management outcomes.
The recommendation reflects growing focus on expanding treatment accessibility and convenience in obesity management through oral therapeutic options.
For patients, the oral formulation may improve convenience and accessibility by providing a non-injectable alternative for long-term weight management while maintaining the therapeutic approach associated with GLP-1 receptor agonists.
From a commercial perspective, the expanded indication strengthens the position of Wegovy within the growing obesity treatment market and supports broader adoption of oral GLP-1 therapies across additional patient populations.
Quick FAQs
1. What did the EMA recommend for Wegovy?
The EMA recommended approval of oral Wegovy (semaglutide) for weight management in adults with obesity or overweight.
2. Why is oral Wegovy significant?
It is the first oral GLP-1 receptor agonist recommended for weight management in the European Union.
3. Which trial programme supported oral Wegovy?
The recommendation was supported by the OASIS clinical development programme evaluating oral semaglutide.
4. What could oral Wegovy mean for patients?
The oral formulation may provide a more convenient non-injectable option for long-term weight management.
